Borgström Fredrik, Kanis John A
Medical Management Centre, Karolinska Institutet, 171 77 Stockholm, Sweden.
Best Pract Res Clin Endocrinol Metab. 2008 Oct;22(5):885-900. doi: 10.1016/j.beem.2008.07.005.
Rather than reviewing the many studies of cost effectiveness in osteoporosis, this paper reviews the principles of cost-effectiveness analysis and the gaps in our knowledge that are required to improve such analyses in osteoporosis. These include more information on the cost of fractures and their consequences on health states, particularly on an international basis. New developments include the incorporation of adherence into models, the use of the FRAX tool to assess cost-effectiveness in individuals with any combination of risk factors for fracture, and the setting of intervention thresholds based on cost-effectiveness.
本文并非回顾骨质疏松症成本效益的众多研究，而是回顾成本效益分析的原则以及我们在知识方面的差距，这些差距是改善骨质疏松症成本效益分析所必需的。这些差距包括更多关于骨折成本及其对健康状况影响的信息，尤其是在国际层面。新进展包括将依从性纳入模型、使用FRAX工具评估具有任何骨折风险因素组合个体的成本效益，以及基于成本效益设定干预阈值。
